On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt, Germany-based company that is not related to the U.S-based Merck & Co (NYSE:MRK).

Merck & Co continues its quest to end cancer.

Meanwhile, Merck & Co just reported first-time positive data for its antibody-drug conjugate therapy aimed at lung and breast cancer patients from its open-label Phase II trial.

At the beginning of June, Merck also released more good news from its three-year study...